Experienced in Small Lymphocytic Lymphoma (SLL)

Dr. Christina E. Henson

Radiation Oncology
Ou Health Partners Inc
900 Ne 10th St, Ouhp Family Medicine, 
Oklahoma City, OK 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Experienced in Small Lymphocytic Lymphoma (SLL)
Ou Health Partners Inc
900 Ne 10th St, Ouhp Family Medicine, 
Oklahoma City, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christina Henson is a Radiation Oncologist in Oklahoma City, Oklahoma. Dr. Henson is rated as an Experienced provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Breast Cancer, and Squamous Cell Skin Carcinoma. Dr. Henson is currently accepting new patients.

Her clinical research consists of co-authoring 41 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Internal Medicine in OK
Hospital Affiliations
O U Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

OU HEALTH PARTNERS INC
900 Ne 10th St, Ouhp Family Medicine, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Phase III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck
Phase III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Single-arm Phase II Trial of Palliative QUAD SHOT Radiotherapy Combined With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
A Single-arm Phase II Trial of Palliative QUAD SHOT Radiotherapy Combined With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma
Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2024
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Elimusertib, Pembrolizumab
Study Phase: Phase 1
View 8 Less Clinical Trials

41 Total Publications

Beneath the surface: When a locally aggressive squamous cell carcinoma is revealed to be a squamoid eccrine ductal carcinoma.
Beneath the surface: When a locally aggressive squamous cell carcinoma is revealed to be a squamoid eccrine ductal carcinoma.
Journal: JAAD case reports
Published: October 13, 2025
Similar Doctors
Experienced in Small Lymphocytic Lymphoma (SLL)
Dr. Shripal K. Bhavsar
Radiation Oncology
Experienced in Small Lymphocytic Lymphoma (SLL)
Dr. Shripal K. Bhavsar
Radiation Oncology

Radiation Medicine Associates, P.C.

4401 S Western Ave, 
Oklahoma City, OK 
 (4.4 miles away)
405-636-7342
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shripal Bhavsar is a Radiation Oncologist in Oklahoma City, Oklahoma. Dr. Bhavsar has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Pleuropulmonary Blastoma, Breast Cancer, Lung Cancer, and Prostate Cancer. Dr. Bhavsar is currently accepting new patients.

Experienced in Small Lymphocytic Lymphoma (SLL)
Dr. Robert C. Gaston
Radiation Oncology
Experienced in Small Lymphocytic Lymphoma (SLL)
Dr. Robert C. Gaston
Radiation Oncology

Radiation Medicine Associates, P.C.

4401 S Western Ave, 
Oklahoma City, OK 
 (4.4 miles away)
405-636-7342
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Gaston is a Radiation Oncologist in Oklahoma City, Oklahoma. Dr. Gaston is rated as a Distinguished provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, and Breast Cancer. Dr. Gaston is currently accepting new patients.

Experienced in Small Lymphocytic Lymphoma (SLL)
Dr. Gary L. Larson
Radiation Oncology
Experienced in Small Lymphocytic Lymphoma (SLL)
Dr. Gary L. Larson
Radiation Oncology

Radiation Medicine Associates, P.C.

5901 W Memorial Rd, 
Oklahoma City, OK 
 (11.5 miles away)
405-773-6700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gary Larson is a Radiation Oncologist in Oklahoma City, Oklahoma. Dr. Larson is rated as a Distinguished provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, Breast Cancer, and Thymectomy. Dr. Larson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Henson's expertise for a condition
ConditionClose
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile